We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.
- Authors
Hayden, Frederick G; Herrington, Darrell T; Coats, Teresa L; Kim, Kenneth; Cooper, Ellen C; Villano, Stephen A; Liu, Siyu; Hudson, Spencer; Pevear, Daniel C; Collett, Marc; McKinlay, Mark; Pleconaril Respiratory Infection Study Group
- Abstract
The novel capsid-binding antiviral pleconaril inhibits in vitro replication of most rhinoviruses and enteroviruses. Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials. Among 1363 picornavirus-infected participants (65%) in the studies combined, the median time to alleviation of illness was 1 day shorter for pleconaril recipients than for placebo recipients (P<.001). Cold symptom scores and frequency of picornavirus cultured from nasal mucus specimens were lower among pleconaril recipients by day 2 of treatment. No treatment effects were seen in those without picornavirus infection. Pleconaril was associated with a higher incidence of nausea (6% vs. 4%) and diarrhea (9% vs. 7%) and with small increases in mean serum cholesterol levels and platelet counts, compared with baseline measurements. A subsequent 6-week prophylaxis study found that pleconaril induces cytochrome P-450 3A enzymes, which metabolize a variety of drugs, including ethinyl estradiol. Early pleconaril treatment was well tolerated and significantly reduced the duration and severity of colds due to picornaviruses in adults.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Vol 36, Issue 12, p1523
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/375069